Navuridine

Drug Profile

Navuridine

Alternative Names: AZDDU; AzddUrd; AZDU; Azidodideoxyuridine; Azidouridine; CS 87

Latest Information Update: 12 Apr 2007

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator University of Georgia
  • Developer Bayer HealthCare Pharmaceuticals
  • Class Antiretrovirals; Nucleosides; Small molecules
  • Mechanism of Action RNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - HIV infections

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 04 Apr 2007 Berlex Inc has been acquired by Bayer HealthCare
  • 16 Oct 1998 A preclinical study has been added to the pharmacodynamics section
  • 06 Sep 1995 Investigation in HIV infections treatment in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top